Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye Ltd prices offering at US$23 per share

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 29, 2023 12:27pm

182 Views

Post# 35661928

RE:RE:RE:RE:RE:RE:RE:RE:Adlai Nortye Ltd prices offering at US$23 per share

Hey Fox, I agree but markets are fickle so IF ESMO comes out with good results and confirms the panc and we get pfs and general OS numbers and they are good and IF the crc is showing that signal to move forward then really I cannot see any way that the sp will not start to move. Also around the timeframe we could finally see the definitive agreements done and signed and if the fda approves the trial arm protocols then I could see the partnership signed. Could happen earlier but this could be a huge inflection point that nobody will be able to ignore IMO of course.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism